

Date Mailed: August 25, 2006

Sheet 1 of 1

FORM 1449*

INFORMATION DISCLOSURE STATEMENT

Docket Number:

15395.0005USWO

Application Number:

10/583805

IN AN APPLICATION

(Use several sheets if necessary)

Applicant: NATARAJAN et al.

Filing Date: June 22, 2006

Group Art Unit: Unknown

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,958,951	09-1999	Ahrndt et al.			
	5,354,760	10-1994	Petersen et al.			
	5,010,090	04-1991	Gronvald et al.			

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Andersen et al. "The Synthesis of Novel GABA Uptake Inhibitors. 1. Elucidation of the Structure-Activity Studies Leading to the Choice of (R)-1-[4,4-Bis(3-methyl-2-thienyl)-3-butenyl]-3-piperidinecarboxylic Acid (Tiagabine) as an Anticonvulsant Drug Candidate" Journal of Medicinal Chemistry, 36 p. 1716-1725 (1993)

23552

PATENT TRADEMARK OFFICE

EXAMINER

/Sun Jae Loewe/

DATE CONSIDERED

08/16/2008

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.